Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
Open Access
- 27 September 2018
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 6 (4), 1-7
- https://doi.org/10.14218/jcth.2018.00007
Abstract
Ribavirin, once a staple of hepatitis C treatment, has significant drawbacks, including treatment-limiting side effects, the requirement for intensive laboratory monitoring, the need for frequent dose adjustments, and teratogenicity. These factors make it difficult to escalate ribavirin-based HCV treatment to most infected patients globally. Most studies have shown comparable response rates between ribavirin-inclusive and ribavirin-sparing regimens in uncomplicated patient populations. However, ribavirin is still used in the management of patients who have failed previous therapy as well as those with decompensated liver disease. In this review, we explore the evidence supporting the use of ribavirin in the current climate of hepatitis C treatment with oral combination direct-acting antiviral agents.Keywords
This publication has 48 references indexed in Scilit:
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment CharacteristicsJAMA, 2013
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsThe New England Journal of Medicine, 2013
- Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?Gut, 2013
- Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDSClinical Infectious Diseases, 2012
- Telaprevir for Retreatment of HCV InfectionThe New England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Antiviral therapy in HCV-infected decompensated cirrhoticsSaudi Journal of Gastroenterology, 2010
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CThe New England Journal of Medicine, 1998
- Ribavirin as Therapy for Chronic Hepatitis CAnnals of Internal Medicine, 1995